|
1 Indications And Usage Entresto Is A Combination Of Sacubitril, A Neprilysin Inhibitor, And Valsartan, An Angiotensin Ii Receptor Blocker Indicated: To Reduce The Risk Of Cardiovascular Death And Hospitalization For Heart Failure In Patients With Chronic Heart Failure (Nyha Class Ii-Iv) And Reduced Ejection Fraction. ( 1.1 ) Entresto Is Usually Administered In Conjunction With Other Heart Failure Therapies, In Place Of An Ace Inhibitor Or Other Arb. ( 1.1 ) For The Treatment Of Symptomatic Heart Failure With Systemic Left Ventricular Systolic Dysfunction In Pediatric Patients Aged One Year And Older. Entresto Reduces Nt-Probnp And Is Expected To Improve Cardiovascular Outcomes. ( 1.2 ) 1.1 Adult Heart Failure Entresto Is Indicated To Reduce The Risk Of Cardiovascular Death And Hospitalization For Heart Failure In Patients With Chronic Heart Failure (Nyha Class Ii-Iv) And Reduced Ejection Fraction. Entresto Is Usually Administered In Conjunction With Other Heart Failure Therapies, In Place Of An Ace Inhibitor Or Other Arb. 1.2 Pediatric Heart Failure Entresto Is Indicated For The Treatment Of Symptomatic Heart Failure With Systemic Left Ventricular Systolic Dysfunction In Pediatric Patients Aged One Year And Older. Entresto Reduces Nt-Probnp And Is Expected To Improve Cardiovascular Outcomes.
|